Literature DB >> 21977338

Treatment of generalized anxiety disorder: a comprehensive review of the literature for psychopharmacologic alternatives to newer antidepressants and benzodiazepines.

John Huh1, Deborah Goebert, Junji Takeshita, Brett Y Lu, Mark Kang.   

Abstract

OBJECTIVE: Generalized anxiety disorder (GAD) is common, chronic, and debilitating. Treatment with benzodiazepines and newer antidepressants is often inadequate. This article reviews the effectiveness of alternative and augmenting medications, such as older antidepressants, antipsychotics, anticonvulsants, and β-blockers. DATA SOURCES: A search using MEDLINE (1980 to week 4 of May 2010) with the key words generalized anxiety disorder or GAD and therapeutics or treatment was conducted. Articles included adult patients with a GAD diagnosis that established chronicity of illness. These included a small number of studies that used DSM-III criteria but added a chronicity of symptoms and included all studies that used DSM-III-R and DSM-IV criteria. Articles that did not include medications or that exclusively focused on newer antidepressants (selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, bupropion, and mirtazapine), buspirone, benzodiazepines, or herbal or investigational medications were excluded. Review articles and non-English-language articles were also excluded.
RESULTS: Thirty-six studies were reviewed. All of the references were then analyzed, and key portions were extracted. Many studies were open trials. Double-blind, placebo-controlled studies with imipramine, risperidone, olanzapine, hydroxyzine, ondansetron, tiagabine, valproate, and pregabalin had been conducted. Imipramine, hydroxyzine, valproate, and pregabalin were the most effective, although risperidone, olanzapine, ziprasidone, and aripiprazole may also reduce symptoms.
CONCLUSIONS: Several medication strategies can be considered as promising alternatives or augmenting to antidepressant or benzodiazepine therapy in GAD.

Entities:  

Year:  2011        PMID: 21977338      PMCID: PMC3184575          DOI: 10.4088/pcc.08r00709blu

Source DB:  PubMed          Journal:  Prim Care Companion CNS Disord        ISSN: 2155-7780


  42 in total

1.  Open-label pilot study of ziprasidone for refractory generalized anxiety disorder.

Authors:  Steven H Snyderman; Moira A Rynn; Karl Rickels
Journal:  J Clin Psychopharmacol       Date:  2005-10       Impact factor: 3.153

2.  An open-label study of tiagabine as augmentation therapy for anxiety.

Authors:  Thomas L Schwartz; Nouman Azhar; Juhi Husain; Nikhil Nihalani; Mihai Simionescu; Douglas Coovert; Shefali Jindal; Syed Tirmazi
Journal:  Ann Clin Psychiatry       Date:  2005 Jul-Sep       Impact factor: 1.567

3.  An open-label trial of risperidone augmentation for refractory anxiety disorders.

Authors:  Naomi M Simon; Elizabeth A Hoge; Diana Fischmann; John J Worthington; Kelly M Christian; Gustavo Kinrys; Mark H Pollack
Journal:  J Clin Psychiatry       Date:  2006-03       Impact factor: 4.384

4.  Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study.

Authors:  Olga Brawman-Mintzer; Rebecca G Knapp; Paul J Nietert
Journal:  J Clin Psychiatry       Date:  2005-10       Impact factor: 4.384

5.  Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine.

Authors:  Stuart A Montgomery; Kathy Tobias; Gwen L Zornberg; Siegfried Kasper; Atul C Pande
Journal:  J Clin Psychiatry       Date:  2006-05       Impact factor: 4.384

6.  Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder.

Authors:  Elizabeth A Hoge; John J Worthington; Rebecca E Kaufman; Hannah R Delong; Mark H Pollack; Naomi M Simon
Journal:  CNS Spectr       Date:  2008-06       Impact factor: 3.790

7.  Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study.

Authors:  Borwin Bandelow; Guy Chouinard; Julio Bobes; Antti Ahokas; Ivan Eggens; Sherry Liu; Hans Eriksson
Journal:  Int J Neuropsychopharmacol       Date:  2009-08-20       Impact factor: 5.176

8.  Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies.

Authors:  Mark H Pollack; Jane Tiller; Fang Xie; Madhukar H Trivedi
Journal:  J Clin Psychopharmacol       Date:  2008-06       Impact factor: 3.153

9.  Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study.

Authors:  Nadir A Aliyev; Zafar N Aliyev
Journal:  Eur Psychiatry       Date:  2007-10-22       Impact factor: 5.361

10.  Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings.

Authors:  Naomi M Simon; Kathryn M Connor; Richard T LeBeau; Elizabeth A Hoge; John J Worthington; Wei Zhang; Jonathan R T Davidson; Mark H Pollack
Journal:  Psychopharmacology (Berl)       Date:  2008-02-02       Impact factor: 4.530

View more
  11 in total

1.  The involvement of magnoflorine in the sedative and anxiolytic effects of Sinomeni Caulis et Rhizoma in mice.

Authors:  June Bryan I de la Peña; Hye Lim Lee; Seo Young Yoon; Gun Hee Kim; Yong Soo Lee; Jae Hoon Cheong
Journal:  J Nat Med       Date:  2013-03-03       Impact factor: 2.343

2.  Of mice and marbles: Novel perspectives on burying behavior as a screening test for psychiatric illness.

Authors:  De Wet Wolmarans; Dan J Stein; Brian H Harvey
Journal:  Cogn Affect Behav Neurosci       Date:  2016-06       Impact factor: 3.282

3.  Brain-derived neurotrophic factor signaling mitigates the impact of acute social stress.

Authors:  Anna M Rosenhauer; Linda Q Beach; Elizabeth C Jeffress; Brittany M Thompson; Katharine E McCann; Katherine A Partrick; Bryan Diaz; Alisa Norvelle; Dennis C Choi; Kim L Huhman
Journal:  Neuropharmacology       Date:  2018-12-14       Impact factor: 5.250

4.  Differential postpartum sensitivity to the anxiety-modulating effects of offspring contact is associated with innate anxiety and brainstem levels of dopamine beta-hydroxylase in female laboratory rats.

Authors:  C M Ragan; J S Lonstein
Journal:  Neuroscience       Date:  2013-10-22       Impact factor: 3.590

5.  A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder.

Authors:  Carl Gommoll; Suresh Durgam; Maju Mathews; Giovanna Forero; Rene Nunez; Xiongwen Tang; Michael E Thase
Journal:  Depress Anxiety       Date:  2015-04-17       Impact factor: 6.505

6.  Herbal medicine use in adults who experience anxiety: A qualitative exploration.

Authors:  Erica McIntyre; Anthony J Saliba; Carmen C Moran
Journal:  Int J Qual Stud Health Well-being       Date:  2015-12-15

7.  Novel drug-regulated transcriptional networks in brain reveal pharmacological properties of psychotropic drugs.

Authors:  Michal Korostynski; Marcin Piechota; Jaroslaw Dzbek; Wiktor Mlynarski; Klaudia Szklarczyk; Barbara Ziolkowska; Ryszard Przewlocki
Journal:  BMC Genomics       Date:  2013-09-08       Impact factor: 3.969

8.  Aligning the many definitions of treatment resistance in anxiety disorders: A systematic review.

Authors:  Wicher A Bokma; Guido A A M Wetzer; Jurriaan B Gehrels; Brenda W J H Penninx; Neeltje M Batelaan; Anton L J M van Balkom
Journal:  Depress Anxiety       Date:  2019-06-23       Impact factor: 6.505

9.  Anxiolytic, Promnesic, Anti-Acetylcholinesterase and Antioxidant Effects of Cotinine and 6-Hydroxy-L-Nicotine in Scopolamine-Induced Zebrafish (Danio rerio) Model of Alzheimer's Disease.

Authors:  Razvan Stefan Boiangiu; Marius Mihasan; Dragos Lucian Gorgan; Bogdan Alexandru Stache; Lucian Hritcu
Journal:  Antioxidants (Basel)       Date:  2021-02-01

10.  Psychogenic Polydipsia - Management Challenges.

Authors:  M S Bhatia; Aparna Goyal; Rashmita Saha; Nimisha Doval
Journal:  Shanghai Arch Psychiatry       Date:  2017-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.